

Title (en)  
MARKERS FOR PROSTATE CANCER

Title (de)  
MARKER FÜR PROSTATAKREBS

Title (fr)  
MARQUEURS DU CANCER DE LA PROSTATE

Publication  
**EP 1208232 A4 20030115 (EN)**

Application  
**EP 00938256 A 20000609**

Priority  
• US 0016007 W 20000609  
• US 32991799 A 19990610

Abstract (en)  
[origin: WO0077258A1] This invention provides a method for determining the aggressiveness of a prostate carcinoma comprising: (a) obtaining a sample of the prostate carcinoma; and (b) detecting the presence of p27 protein in the prostate carcinoma, the absence of p27 indicating that the prostate carcinoma is aggressive. This invention also provides a method for diagnosing a benign prostate hyperplasia comprising: (a) obtaining an appropriate sample of the hyperplasia; and (b) detecting the presence of the p27 RNA, a decrease of the p27 RNA indicating that the hyperplasia is benign. This invention provides various uses of p27 in prostate cancer. Finally, this invention also provides different marker for prostate cancer.

IPC 1-7  
**C12Q 1/68; C07H 21/04; G01N 33/574**

IPC 8 full level  
**C07H 21/04** (2006.01); **C12Q 1/68** (2006.01); **C12Q 1/6886** (2018.01); **G01N 33/574** (2006.01)

CPC (source: EP)  
**C12Q 1/6886** (2013.01); **G01N 33/57434** (2013.01); **C12Q 2600/118** (2013.01); **G01N 2333/71** (2013.01)

Citation (search report)

- [XY] WO 9904238 A2 19990128 - MITOTIX INC [US], et al
- [XY] WO 9833450 A1 19980806 - PORTER PEGGY L [US], et al
- [Y] WO 9422478 A1 19941013 - UNIV PENNSYLVANIA [US], et al
- [PX] WO 9931140 A1 19990624 - GENENTECH INC [US]
- [XY] CORDON-CARDO C ET AL: "DISTINCT ALTERED PATTERNS OF P27 GENE EXPRESSION IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATIC CARCINOMA", JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDUCATION AND WELFARE, PUBLIC HEALTH, US, vol. 17, no. 90, 2 September 1998 (1998-09-02), pages 1284 - 1291, XP001080206, ISSN: 0027-8874
- [XY] COTE RICHARD J ET AL: "Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma.", JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), vol. 90, no. 12, 17 June 1998 (1998-06-17), pages 916 - 920, XP002931303, ISSN: 0027-8874
- [XY] LLOYD RICARDO V ET AL: "p27Kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers.", AMERICAN JOURNAL OF PATHOLOGY, vol. 154, no. 2, February 1999 (1999-02-01), pages 313 - 323, XP002931302, ISSN: 0002-9440
- [XY] GUO Y ET AL: "Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES DEC 1997, vol. 3, no. 12 Pt 1, December 1997 (1997-12-01), pages 2269 - 2274, XP002916572, ISSN: 1078-0432
- [XY] MARZO DE ANGELO M ET AL: "Prostate stem cell compartments: Expression of the cell cycle inhibitor p27kip1 in normal, hyperplastic, and neoplastic cells", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 153, no. 3, September 1998 (1998-09-01), pages 911 - 919, XP002199162, ISSN: 0002-9440
- [XY] FERNÁNDEZ P L ET AL: "Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression.", THE JOURNAL OF PATHOLOGY. ENGLAND APR 1999, vol. 187, no. 5, April 1999 (1999-04-01), pages 563 - 566, XP002199163, ISSN: 0022-3417
- [X] MCARTHUR J G ET AL: "Cancer gene therapy with novel chimeric p27/p16 tumor suppressor genes.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03-01), 90th Annual Meeting of the American Association for Cancer Research; Philadelphia, Pennsylvania, USA; April 10-14, 1999, March, 1999, pages 630, XP002144030, ISSN: 0197-016X
- [Y] CARIOU S ET AL: "PROGNOSTIC IMPLICATIONS OF EXPRESSION OF THE CELL CYCLE INHIBITOR PROTEIN P27", BREAST CANCER RESEARCH AND TREATMENT, NIJHOFF, BOSTON, US, vol. 1-3, no. 52, 1998, pages 29 - 41, XP001080251, ISSN: 0167-6806
- [X] AALTOMAA S ET AL: "Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer.", THE PROSTATE. UNITED STATES 1 APR 1999, vol. 39, no. 1, 1 April 1999 (1999-04-01), pages 8 - 15, XP002213568, ISSN: 0270-4137
- [X] BARETTON G B ET AL: "Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.", BRITISH JOURNAL OF CANCER. SCOTLAND MAY 1999, vol. 80, no. 3-4, May 1999 (1999-05-01), pages 546 - 555, XP002213569, ISSN: 0007-0920
- [X] YAMASAKI ICHIRO ET AL: "Overexpression of MDM2 and p53 protein is infrequently but significantly associated with progression of human prostatic adenocarcinoma.", ONCOLOGY REPORTS, vol. 3, no. 5, 1996, pages 925 - 929, XP002213570, ISSN: 1021-335X
- [X] DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 1999 (1999-03-01), LEE TAE YOON ET AL: "Immunohistochemical expression of p53 and MDM-2 protein in various epithelial carcinomas.", XP002213577, Database accession no. PREV199900406745 & CHUNG-ANG JOURNAL OF MEDICINE, vol. 24, no. 1, March 1999 (1999-03-01), pages 1 - 11, ISSN: 0253-6250
- [XY] HAN EDWARD KYU-HO ET AL: "Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors.", PROSTATE, vol. 35, no. 2, May 1998 (1998-05-01), pages 95 - 101, XP002213571, ISSN: 0270-4137
- [XY] GUMBINER LAURA M ET AL: "Overexpression of cyclin D1 is rare in human prostate carcinoma.", PROSTATE, vol. 38, no. 1, 1 January 1999 (1999-01-01), pages 40 - 45, XP001105184, ISSN: 0270-4137
- [XY] CHEN Y ET AL: "Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1.", ONCOGENE. ENGLAND 16 APR 1998, vol. 16, no. 15, 16 April 1998 (1998-04-16), pages 1913 - 1920, XP002213572, ISSN: 0950-9232
- [X] LEE C T ET AL: "OVEREXPRESSION OF THE CYCLIN-DEPENDENT KINASE INHIBITOR P16 IS ASSOCIATED WITH TUMOR RECURRENCE IN HUMAN PROSTATE CANCER", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 5, no. 5, May 1999 (1999-05-01), pages 977 - 983, XP001016336, ISSN: 1078-0432
- [X] CURNOW R T: "CLINICAL EXPERIENCE WITH CD64-DIRECTED IMMUNOTHERAPY. AN OVERVIEW", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, vol. 45, no. 3/4, November 1997 (1997-11-01), pages 210 - 215, XP000918956, ISSN: 0340-7004

- [X] JAMES N ET AL: "PHASE II TRIAL OF THE BISPECIFIC ANTIBODY MDX-H210 (ANTI-HER2/NEU X ANTI-CD64) COMBINED WITH GM-CSF IN PATIENTS WITH ADVANCED PROSTATE AND RENAL CELL CARCINOMAS THAT EXPRESS HER2/NEU", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 78, no. SUPPL 2, 5 July 1998 (1998-07-05), pages 19, XP000940750, ISSN: 0007-0920
- [XY] ZHAU H E ET AL: "Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines.", MOLECULAR CARCINOGENESIS. UNITED STATES 1992, vol. 5, no. 4, 1992, pages 320 - 327, XP002213573, ISSN: 0899-1987
- [X] VELTRI ROBERT W ET AL: "Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 image analysis systems, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression.", JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT, no. 19, 1994, pages 249 - 258, XP002213574, ISSN: 0733-1959
- [X] ROSS JEFFREY S ET AL: "Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis.", CANCER (PHILADELPHIA), vol. 72, no. 10, 1993, pages 3020 - 3028, XP002214671, ISSN: 0008-543X
- [X] ARAI YOICHI ET AL: "C-erbB-2 Oncoprotein: A potential biomarker of advanced prostate cancer.", PROSTATE, vol. 30, no. 3, 1997, pages 195 - 201, XP002214672, ISSN: 0270-4137
- [Y] KOENEMAN K S ET AL: "OSTEOMIMETIC PROPERTIES OF PROSTATE CANCER CELLS: A HYPOTHESIS SUPPORTING THE PREDILECTION OF PROSTATE CANCER METASTASIS AND GROWTH IN THE BONE ENVIRONMENT", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 39, 1999, pages 246 - 261, XP002946861, ISSN: 0270-4137
- [Y] CRAFT NOAH ET AL: "A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.", NATURE MEDICINE, vol. 5, no. 3, March 1999 (1999-03-01), pages 280 - 285, XP002213575, ISSN: 1078-8956
- [Y] BASELGA J ET AL: "RECOMBINANT HUMANIZED ANTI-HER2 ANTIBODY (HERCEPTIN TM) ENHANCES THE ANTITUMOR ACTIVITY OF PACLITAXEL AND DOXORUBICIN AGAINST HER2/NEU OVEREXPRESSING HUMAN BREAST CANCER XENOGRAFTS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 58, no. 13, 1998, pages 2825 - 2831, XP000919190, ISSN: 0008-5472
- [PX] OSMAN I ET AL: "Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES AUG 1999, vol. 5, no. 8, August 1999 (1999-08-01), pages 2082 - 2088, XP002213576, ISSN: 1078-0432
- [PX] AGUS D B ET AL: "RESPONSE OF PROSTATE CANCER TO ANTI-HER-2/NEU ANTIBODY IN ANDROGEN DEPENDENT AND - INDEPENDENT HUMAN XENOGRAFT MODELS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, 1 October 1999 (1999-10-01), pages 4761 - 4764, XP000919490, ISSN: 0008-5472
- See references of WO 0077258A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

**WO 0077258 A1 20001221**; CA 2375228 A1 20001221; EP 1208232 A1 20020529; EP 1208232 A4 20030115; EP 1512755 A2 20050309; EP 1512755 A3 20071121

DOCDB simple family (application)

**US 0016007 W 20000609**; CA 2375228 A 20000609; EP 00938256 A 20000609; EP 04023000 A 20000609